NDA 021119 · Bausch Lomb Ireland
Visudyne
Verteporfin · Injection · Photoenhancer
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Feb 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Apr 12, 2000
Approved uses
3
Original approval plus efficacy supplements
Registered trials
90
19 Phase 3, 4 recruiting
FAERS reports
1,481
1,316 serious, 59 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 27, 2025.
VISUDYNE ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate VISUDYNE for the treatment of predominantly occult subfoveal CNV. VISUDYNE (verteporfin for injection) therapy is a photoenhancer indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. ( 1 )
Mechanism: VISUDYNE (verteporfin for injection) therapy is a two-stage process requiring administration of both verteporfin for injection and nonthermal red light. Verteporfin is transported in the plasma primarily by lipoproteins. Once verteporfin is activated by light in the presence of oxygen, highly reactive, short-lived singlet oxygen and reactive oxygen radicals are generated. Light activation of verteporfin results in local damage to neovascular endothelium, resulting in vessel occlusion. Damaged endothelium is known to release procoagulant and vasoactive factors through the lipoxygenase...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 30, 2008 Supplement 13 · Efficacy LetterLabel
- Aug 22, 2001 Supplement 1 · Efficacy · priority review LabelReviewLetter
- Apr 12, 2000 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterReviewLabel
1 products under this application
- VISUDYNE · VERTEPORFIN 15MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Verteporfin" as an intervention, any sponsor and status, largest first.
Kagawa UniversityAcademic, hospital or other
NCT02321267 · 1,000 participants (planned) · Start Dec 2014 · Primary completion Dec 2024
Drug: ranibizumab, aflibercept, pegaptanib, verteporphin · For: Macular Disease
Sites: Hiragi, Japan
- Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMDPivotal-lookingCompleted
Alcon ResearchIndustry
NCT00041483 · 530 participants · Start Jun 2002 · Primary completion Aug 2005
Drug: Anecortave Acetate 15 mg sterile suspension · For: Macular Degeneration
Sites: Fort Worth, Texas
- Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic MyopiaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01922102 · 457 participants · Start Sep 11, 2013 · Primary completion Sep 14, 2016
Drug: Ranibizumab 0.5mg; Ranibizumab 0.5 mg and 1 more · For: Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)
Sites: Beijing, China; Chongqing, China; Shantou, China · 47 sites in all
- A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular DegenerationPivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00061594 · 426 participants · Start May 2003
Drug: rhuFab V2 (ranibizumab) · For: Macular Degeneration
Sites: Tucson, Arizona; Beverly Hills, California; Irvine, California · 82 sites in all
- Visudyne® in Occult (VIO)Pivotal-lookingCompleted
QLT Inc.Industry
NCT00121407 · 364 participants · Start Mar 2002
Drug: Visudyne for injection · For: Macular Degeneration
- Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)Pivotal-lookingTerminated
Eyetech PharmaceuticalsIndustry
NCT00134667 · 360 participants · Start Mar 2005
Drug: Photodynamic Therapy (PDT) with Visudyne (verteporfin); Macugen (pegaptanib sodium) · For: Age-Related Macular Degeneration
Sites: Tucson, Arizona
- Aflibercept in Polypoidal Choroidal VasculopathyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT02120950 · 333 participants · Start May 29, 2014 · Primary completion Aug 12, 2016
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) · For: Neovascular Macular Degeneration
Sites: Liverpool, Australia; Strathfield, Australia; Westmead, Australia · 62 sites in all
- Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01846273 · 321 participants · Start Aug 7, 2013 · Primary completion Mar 11, 2016
Drug: Ranibizumab; Verteporfin PDT and 1 more · For: Age-related Macular Degeneration; Polypoidal Choroidal Vasculopathy
Sites: Hong Kong, Hong Kong; Nagoya, Japan; Fukuoka, Japan · 41 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- visual acuity reduced399
- retinal haemorrhage212
- disease progression173
- off label use140
- polypoidal choroidal vasculopathy134
- choroidal neovascularisation99
- age-related macular degeneration87
- retinal pigment epithelial tear74
- retinal detachment66
- vitreous haemorrhage63
- detachment of retinal pigment epithelium58
- macular degeneration58
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 101 |
| 2005 | 147 |
| 2006 | 99 |
| 2007 | 81 |
| 2008 | 69 |
| 2009 | 58 |
| 2010 | 66 |
| 2011 | 110 |
| 2012 | 46 |
| 2013 | 18 |
| 2014 | 35 |
| 2015 | 43 |
| 2016 | 94 |
| 2017 | 254 |
| 2018 | 136 |
| 2019 | 56 |
| 2020 | 22 |
| 2021 | 12 |
| 2022 | 7 |
| 2023 | 11 |
| 2024 | 6 |
| 2025 | 3 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Visudyne (Verteporfin) · HCPCS J3396
2024 spending
$1.6M
Beneficiaries
851
970 claims
Per beneficiary
$1,857
2024 ASP limit $11.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,648,687 |
| 2021 | $2,537,428 |
| 2022 | $1,812,800 |
| 2023 | $1,671,833 |
| 2024 | $1,580,514 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Photodynamic therapy].
Soubrane G, Kuhn D, Oubraham H, et al. · J Fr Ophtalmol 2002 · Clinical Trial, English Abstract
- Age related macular degeneration.
Arnold JJ, Heriot W · BMJ Clin Evid 2007 · Systematic Review
- Verteporfin infusion-associated pain.
Borodoker N, Spaide RF, Maranan L, et al. · Am J Ophthalmol 2002 · Clinical Trial, Controlled Clinical Trial
- Photodynamic therapy for choroidal melanoma: What is the response rate?
Yordi S, Soto H, Bowen RC, et al. · Surv Ophthalmol 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Research progress of hydroxychloroquine and autophagy inhibitors on cancer.
Shi TT, Yu XX, Yan LJ, et al. · Cancer Chemother Pharmacol 2017 · Systematic Review
- Cost effectiveness of treatments for wet age-related macular degeneration.
Mitchell P, Annemans L, White R, et al. · Pharmacoeconomics 2011 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Bausch Lomb Ireland
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.